# Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

> clinical trial · VERIFIED · 2026-07-30

Status: RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Advanced Lung Non-Squamous Non-Small Cell Carcinoma

- Company: National Cancer Institute (NCI)
- Sector: Advanced Lung Non-Squamous Non-Small Cell Carcinoma
- Primary source: https://clinicaltrials.gov/study/NCT04181060

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.